Scheduled to present at 3 p.m. based on updated agenda
NEWARK, Del., Aug. 22 /PRNewswire-FirstCall/ -- Strategic Diagnostics
Inc. (Nasdaq: SDIX) -- a leading provider of biotechnology-based detection
solutions for a broad range of food, water, agricultural, environmental and
life science applications, announced today that due to a change in the
conference agenda, SDI's presentation at the Roth Capital Partner's Roth
2007 New York Conference at the Westin Hotel in Manhattan is now scheduled
for 3 p.m. on Sept 5, 2007 in the Majestic II (Track 1) room.
The presentation will be webcast at
http://www.wsw.com/webcast/roth13/sdix/ for approximately 30 days following
the conclusion of the presentation. Following the presentation, Mr. Knight
will attend a breakout session. One-on-one meetings may be scheduled
through Roth Capital Partners by calling (949) 720-5700.
Each presentation is designed to provide analysts, institutional
brokers and portfolio managers with an overview of the Company's expertise
in the production of antibodies, used both in diagnostic tests and provided
to the proteomics, pharmaceutical, diagnostics and biomedical research
industries to enable rapid discovery and commercialization of products.
Strategic Diagnostics is a leader in the food pathogen industry, providing
comprehensive, accurate, and easy-to-use tests including the recently
introduced RapidChek(R) SELECT(TM) Salmonella product. The Company is also
an emerging leader in producing monoclonal and polyclonal antibodies for
the pharmaceutical and research industries. The Company's patent-pending
technology also addresses renewable energy opportunities and can be used to
increase efficiency in the production of ethanol. Management will discuss
the recurring revenue component of the Company's business model, revenue
potential from new product and services, and the Company's strategy for
sustainable growth.
About the Roth Capital Partners and the 2007 New York Conference
Roth is one of the last remaining independent full-service investment
banks dedicated to the small and micro-cap market. The firm is privately
owned with current principals being majority owners. The core management
team has been consistent for many years. Since the inception of the firm in
1984, Roth has been a leader and innovator in the small and micro cap
markets. Roth's exclusive focus has been, is, and will continue to offer a
full spectrum of investment banking services, including raising capital,
research coverage, trading and market making, merger and acquisition
advisory services, and investor conferences. Roth's award-winning research
is the foundation of its firm and key to its understanding of the micro-and
small- cap sector. This research, when combined with a seasoned
institutional sales team and its highly visible investor conferences,
creates an unparalleled institutional sponsorship platform for growth
companies. Roth has raised more than $10 billion for small and micro cap
public companies and completed over 135 merger, acquisition and advisory
assignments. Since year 2000, Roth has been a leading placement agent for
the number of PIPE transactions, raising over $2 billion for its clients.
Roth received top 20 IPO aftermarket performance rankings for six
consecutive years from 1994 to 1999. The 5th Annual New York Conference is
a two-day event with more than 230 presenting companies and is attended by
over 1,200 buy side investors. The 2006 conference had more than 2,000
one-on-one meetings.
About Strategic Diagnostics Inc.
Strategic Diagnostics Inc. develops, manufactures and markets
biotechnology-based detection solutions to a diverse customer base, across
multiple industrial and human health markets. By applying its core
competency of creating custom antibodies to assay development, the Company
produces unique, sophisticated diagnostic testing and reagent systems that
are responsive to customer diagnostic and information needs. Customers
benefit with quantifiable "return on investment" by reducing time, labor,
and/or material costs. All this is accomplished while increasing accuracy,
reliability and actionability of essential test results. The Company is
focused on sustaining this competitive advantage by leveraging its
expertise in immunology, proteomics, bio-luminescence and other
bio-reactive technologies to continue its successful customer-focused
research and development efforts. Recent innovations in high throughput
production of antibodies from genetic antigens will complement the
Company's established leadership in commercial and custom antibody
production for the Research, Human/Animal Diagnostics, and Pharmaceutical
industries, and position the Company for broader participation in
proteomics research and discovery.
This news release contains forward-looking statements reflecting SDI's
current expectations. When used in this press release, the words
"anticipate", "could", "enable", "estimate", "intend", "expect", "believe",
"potential", "will", "should", "project", "plan" and similar expressions as
they relate to SDI are intended to identify said forward-looking
statements. Investors are cautioned that all forward-looking statements
involve risks and uncertainties, which may cause actual results to differ
from those anticipated by SDI at this time. Such risks and uncertainties
include, without limitation, changes in demand for products, delays in
product development, delays in market acceptance of new products, retention
of customers and employees, adequate supply of raw materials, inability to
obtain or delays in obtaining fourth party, including AOAC, or required
government approvals, the ability to meet increased market demand,
competition, protection of intellectual property, non-infringement of
intellectual property, seasonality, and other factors more fully described
in SDI's public filings with the U.S. Securities and Exchange Commission.
Company Contact: Investor Contact:
Stan Fronczskowski Hayden Communications
Chief Financial Officer Brett Maas (brett@haydenir.com)
(302) 456-6789 (646) 536-7331
http://www.sdix.com
SOURCE Strategic Diagnostics Inc.
 back to top
Related links:
http://www.sdix.com
http://www.wsw.com/webcast/roth13/sdix
CONTACT:
Stan Fronczskowski, Chief Financial Officer
of Strategic Diagnostics Inc., +1-302-456-6789; or Brett Maas of
Hayden Communications, +1-646-536-7331, brett@haydenir.com, for
Strategic Diagnostics Inc.
|
